Rivastigmine Market 2021 Strong Development By Major Eminent Players, Research Analysis and Forecasts to 2028 | Actavis Pharma, Apotex Corporation.

𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐢𝐯𝐚𝐬𝐭𝐢𝐠𝐦𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭

Rivastigmine is a cholinesterase enzyme inhibitor, which acts on butylcholinesterase and acetylcholinesterase. It is a cholinergic agent that aids in the treatment of Alzheimer’s and Parkinson’s disease. The drug can be administered orally or in transdermal patches form, owing to its small molecular size.

𝐓𝐨 𝐆𝐞𝐭 𝐦𝐨𝐫𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐒𝐭𝐚𝐭𝐞𝐫𝐠𝐢𝐞𝐬 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 –https://www.coherentmarketinsights.com/insight/request-sample/2407

𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐢𝐯𝐚𝐬𝐭𝐢𝐠𝐦𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬

Increasing geriatric population is a major driver for the growth of the global rivastigmine market. According to the Alzheimer Association, in 2018, the risk of suffering from dementia can increase double fold above the age of 65 years in every 5 years. Moreover, surging prevalence of cardiovascular diseases worldwide also accounts for the development of Alzheimer’s disease, thereby augmenting the demand for rivastigmine. As per a report published by the National Center for Biotechnology Information in 2013, the incidence of cardiovascular diseases was around 22.5 per 1,000 person worldwide which in turn suggesting a risk of dementia. Diseases such as diabetes and blood pressure can also elevate the risk of dementia, which would further boost the demand for rivastigmine, thereby accelerating the global market growth.

𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐢𝐯𝐚𝐬𝐭𝐢𝐠𝐦𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 – 𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬

North America accounted for the largest share in the global rivastigmine market in 2017, owing to the increasing prevalence of chronic kidney disease in the region. According to The American Kidney Fund, around 31 million people suffered from chronic kidney disease in 2015. Europe accounted for the second largest share in terms of revenue in the global rivastigmine market, in 2017 owing to increasing geriatric population in the region. Geriatric population is more prone to dementia. According to World Population Prospects (WPP), in 2017, around 25% of the population in Europe was aged 60 years or above. According to the Alzheimer’s Association, in 2017, there was significant prevalence of vascular diseases in Latin America and Africa. Therefore, Latin America and Africa are expected to witness significant market growth during the projected period.

𝐓𝐨 𝐊𝐧𝐨𝐰 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐇𝐞𝐫𝐞 @ https://www.coherentmarketinsights.com/insight/request-pdf/2407

𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐢𝐯𝐚𝐬𝐭𝐢𝐠𝐦𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 – 𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐁𝐚𝐜𝐤𝐠𝐫𝐨𝐮𝐧𝐝

The most prominent players operating in the global rivastigmine market include Novartis Europharm Limited, Actavis Pharma, Apotex Corporation, Aurobindo Pharm Ltd., Teva Pharmaceuticals Industries Ltd., and Dr. Reddy’s Laboratories, Macleods.

These companies are focused on product development and approvals in order to enhance their global market share. For instance, in 2007, the U.S. FDA approved Exelon (Rivastigmine tartarate) — developed by Novartis Europharm Limited for the treatment of Alzheimer's and Parkinson's disease.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐚𝐱𝐨𝐧𝐨𝐦𝐲

On the basis of disease indication:
• Alzheimer’s disease
• Parkinson’s disease

Based on formulation:
• Capsules
• Transdermal Patches

By distribution channel:
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By geography:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

𝐓𝐨 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐚𝐧𝐝 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 –https://www.coherentmarketinsights.com/insight/buy-now/2407

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.